Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 4-Week, Phase II, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease
Brief Summary: This study aims to characterize the relationship between dose of GSK1278863 and hemoglobin (Hgb) response in hemodialysis-dependent (HDD) subjects with anemia associated with chronic kidney disease (CKD). It is anticipated that the data generated will enable selection of the starting dose(s) and optimize dose adjustment regimen(s) for Phase 3 clinical trials. This study will consist of a screening phase of 3-9 weeks, a 4-week treatment phase and a follow-up visit approximately 4 weeks after completing treatment.


Options:
A: Arm Label: Daprodustat; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat tablets, Drug: Saline vials or bags | Arm Label: Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Matching placebo tablets, Drug: Epoetin alfa vials | Intervention Type: DRUG; Name: Daprodustat tablets; Assigned to Arm(s): Daprodustat | Intervention Type: DRUG; Name: Matching placebo tablets; Assigned to Arm(s): Epoetin alfa | Intervention Type: DRUG; Name: Epoetin alfa vials; Assigned to Arm(s): Epoetin alfa | Intervention Type: DRUG; Name: Saline vials or bags; Assigned to Arm(s): Daprodustat
B: Arm Label: GSK1278863 4 milligrams (mg); Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 6 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 8 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 10 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GSK1278863; Assigned to Arm(s): GSK1278863 10 mg, GSK1278863 4 milligrams (mg), GSK1278863 6 mg, GSK1278863 8 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: GSK1278863 4 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 6 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 8 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 10 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 12 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: rhEPO | Intervention Type: DRUG; Name: GSK1278863; Assigned to Arm(s): GSK1278863 10 mg, GSK1278863 12 mg, GSK1278863 4 mg, GSK1278863 6 mg, GSK1278863 8 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: rhEPO; Assigned to Arm(s): Control
D: Arm Label: Desidustat oral tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desidustat Oral Tablet | Arm Label: Epoetin Injection; Type: EXPERIMENTAL; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: Desidustat Oral Tablet; Assigned to Arm(s): Desidustat oral tablet | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin Injection

Answer: B